ReviewMolecules (Basel, Switzerland)2023
Lipoprotein(a) in Atherosclerotic Diseases: From Pathophysiology to Diagnosis and Treatment.
Review in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 95 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
95 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Determinants of Cardiovascular Disease Risk Among LGBTQ+ Populations: A Systematic Review of Empirical Evidence.Nursing open · 2026Pooled it
- Lipoprotein(a) as a Predictor of Cardiovascular Risk in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review.Reviews in cardiovascular medicine · 2025Pooled it
- Lipoprotein (a) in the Development and Progression of Diabetic Retinopathy: A Systematic Review and Meta-Analysis.Medicina (Kaunas, Lithuania) · 2025Pooled it
- Impact of elevated lipoprotein(a) levels on the functional outcomes of ischemic stroke patients: A systematic review and meta-analysis.European journal of neurology · 2024Pooled it
- The effects of colchicine on lipoprotein(a)- and oxidized phospholipid-associated cardiovascular disease risk.European journal of preventive cardiology · 2025Trial
- Substantial Change Between Repeated Lipoprotein(a) Measurements Is Associated with Residual Cardiovascular Risk in a Real-World Multicenter Cohort.Journal of clinical medicine · 2026Article
- Lipoprotein(a) Distribution and Cardiovascular Risk in Japan: Insights from a Multi-center LEAP Study.Journal of atherosclerosis and thrombosis · 2026Article
- Combined prognostic value of elevated lipoprotein(a) and severe calcification for limb outcomes after endovascular therapy.Heart and vessels · 2026Article
- Rethinking Lipid Burden and the Role of Non-LDL Biomarkers in Stroke Risk Stratification.Current atherosclerosis reports · 2026Review
- Lipoprotein(a) -Related Cognitive Vulnerability After Stroke Beyond High-Sensitivity C-Reactive Protein.Translational stroke research · 2026Article
- Sex- and menopause-specific inverse associations between metabolic dysfunction-associated steatotic liver disease and serum lipoprotein(a) concentrations: evidence from SHIP and UK Biobank.Cardiovascular diabetology · 2026Article
- Association of lipoprotein(a) with left ventricular dysfunction in patients with chronic total occlusion of the coronary artery.BMC cardiovascular disorders · 2026Article
- Lipid metabolism, microglia, and stroke.Neural regeneration research · 2026Article
- The Association Between Lipoprotein(a) and Atherosclerotic Cardiovascular Disease Severity.Reviews in cardiovascular medicine · 2026Article
- Review
- Lipoprotein(a) and acute myocardial infarction: Differential risk across age and sex subgroups.The Journal of international medical research · 2026Article
- Causal inference and mediating pathways of metabolic syndrome on calcific aortic valve stenosis: linkage disequilibrium score regression and two-sample, two-step mendelian randomization study.Journal of cardiothoracic surgery · 2026Article
- Early Post-Transplant Changes in Lipoprotein(a), Autotaxin Activity, and Lipid Profile: A Prospective Observational Study of Tacrolimus-Treated Kidney Transplant Recipients in Poland.International journal of molecular sciences · 2026Observational
- Hepatic targeting in ASCVD: integrating lipid lowering and inflammation modulation from statins to gene editing.Journal of translational medicine · 2026Review
- Low early-pregnancy serum lipoprotein(a) as an independent associated factor for gestational diabetes mellitus: a retrospective cohort study.Frontiers in endocrinology · 2026Article
35 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lipoprotein(a) (Lp(a)) is a low-density lipoprotein (LDL) cholesterol-like particle bound to apolipoprotein(a). Increased Lp(a) levels are an independent, heritable causal risk factor for atherosclerotic cardiovascular disease (ASCVD) as they are largely determined by variations in the Lp(a) gene (LPA) locus encoding apo(a). Lp(a) is the preferential lipoprotein carrier for oxidized phospholipids (OxPL), and its role adversely affects vascular inflammation, atherosclerotic lesions, endothelial function and thrombogenicity, which pathophysiologically leads to cardiovascular (CV) events. Despite this crucial role of Lp(a), its measurement lacks a globally unified method, and, between different laboratories, results need standardization. Standard antilipidemic therapies, such as statins, fibrates and ezetimibe, have a mediocre effect on Lp(a) levels, although it is not yet clear whether such treatments can affect CV events and prognosis. This narrative review aims to summarize knowledge regarding the mechanisms mediating the effect of Lp(a) on inflammation, atherosclerosis and thrombosis and discuss current diagnostic and therapeutic potentials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.